title: Loss of miR-126 is crucial to pancreatic cancer progression.
abstract: The tumor-suppressor miRNA 126 (miR-126) is downregulated in many tumors and has recently been placed at the heart of complex metastatic pathways. Hamada and colleagues have identified miR-126 as being downregulated in pancreatic ductal adenocarcinoma (PDAC) patient samples and cell lines. The protein ADAM9 has been implicated in the progression of various solid tumors including PDAC. ADAM9 is overexpressed in PDAC and also a direct target of miR-126. The miR-126/ADAM9 axis was subsequently established to control migration and invasion in PDAC, as well as reversal of epithelial-to-mesenchymal transition. miR-126 is also known to target other crucial oncogenes in PDAC such as KRAS and CRK. Replacing miR-126 in PDAC patients may be a novel strategy for preventing progression and metastasis.
authors: HPB Surgical Unit, Department of Surgery & Cancer, Imperial College, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK. a.frampton@imperial.ac.uk
authors: Adam E
authors: AE
authors: Frampton
authors: Jonathan
authors: J
authors: Krell
authors: Jimmy
authors: J
authors: Jacob
authors: Justin
authors: J
authors: Stebbing
authors: Leandro
authors: L
authors: Castellano
authors: Long R
authors: LR
authors: Jiao